MEK2 inhibitor

DRUG CLASS:

MEK2 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

NRAS mutation	Melanoma	NRAS mutation	Melanoma	FCN-159 Sensitive: C2 – Inclusion Criteria FCN-159 Sensitive : C2	FCN-159 Sensitive: C2 – Inclusion Criteria FCN-159 Sensitive : C2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	HL-085 Sensitive: C2 – Inclusion Criteria HL-085 Sensitive : C2	HL-085 Sensitive: C2 – Inclusion Criteria HL-085 Sensitive : C2
BRAF V600E	Glioma	BRAF V600E	Glioma	FCN-159 Sensitive: C2 – Inclusion Criteria FCN-159 Sensitive : C2	FCN-159 Sensitive: C2 – Inclusion Criteria FCN-159 Sensitive : C2
NRAS Q61	Melanoma	NRAS Q61	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS G13R	Melanoma	NRAS G13R	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS Q61R	Melanoma	NRAS Q61R	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS Q61L	Melanoma	NRAS Q61L	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS Q61K	Melanoma	NRAS Q61K	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS G12D	Melanoma	NRAS G12D	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS G12S	Melanoma	NRAS G12S	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
MSI-L/dMMR	Colorectal Cancer	MSI-L/dMMR	Colorectal Cancer	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3
BRAF mutation + MSI-L/dMMR	Colorectal Cancer	BRAF mutation + MSI-L/dMMR	Colorectal Cancer	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3
NF1 mutation	Glioma	NF1 mutation	Glioma	FCN-159 Sensitive: C3 – Early Trials FCN-159 Sensitive : C3	FCN-159 Sensitive: C3 – Early Trials FCN-159 Sensitive : C3
KIAA1549-BRAF fusion	Glioma	KIAA1549-BRAF fusion	Glioma	FCN-159 Sensitive: C3 – Early Trials FCN-159 Sensitive : C3	FCN-159 Sensitive: C3 – Early Trials FCN-159 Sensitive : C3
BRAF V600	Thyroid Gland Papillary Carcinoma	BRAF V600	Thyroid Gland Papillary Carcinoma	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3
BRAF V600	Non Small Cell Lung Cancer	BRAF V600	Non Small Cell Lung Cancer	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3
BRAF V600	Pancreatic Ductal Adenocarcinoma	BRAF V600	Pancreatic Ductal Adenocarcinoma	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3
BRAF V600	Colorectal Cancer	BRAF V600	Colorectal Cancer	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3	vemurafenib + HL-085 Sensitive: C3 – Early Trials vemurafenib + HL-085 Sensitive : C3
BRAF L597S	Melanoma	BRAF L597S	Melanoma	REC-4881 Sensitive: C4 – Case Studies REC-4881 Sensitive : C4	REC-4881 Sensitive: C4 – Case Studies REC-4881 Sensitive : C4
GNA11 Q209L	Uveal Melanoma	GNA11 Q209L	Uveal Melanoma	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D
ESRP1-RAF1 fusion	Prostate Cancer	ESRP1-RAF1 fusion	Prostate Cancer	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D
SLC45A3-BRAF fusion	Prostate Cancer	SLC45A3-BRAF fusion	Prostate Cancer	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	ceritinib + U0126 Sensitive: D – Preclinical ceritinib + U0126 Sensitive : D	ceritinib + U0126 Sensitive: D – Preclinical ceritinib + U0126 Sensitive : D
MAP2K1 C121S	Melanoma	MAP2K1 C121S	Melanoma	E6201 Sensitive: D – Preclinical E6201 Sensitive : D	E6201 Sensitive: D – Preclinical E6201 Sensitive : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	sotorasib + IMM-1-104 Sensitive: D – Preclinical sotorasib + IMM-1-104 Sensitive : D	sotorasib + IMM-1-104 Sensitive: D – Preclinical sotorasib + IMM-1-104 Sensitive : D
TERT overexpression	Renal Cell Carcinoma	TERT overexpression	Renal Cell Carcinoma	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D
NRAS G12D	Acute Lymphocytic Leukemia	NRAS G12D	Acute Lymphocytic Leukemia	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D
GNAQ Q209P	Uveal Melanoma	GNAQ Q209P	Uveal Melanoma	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D	REC-4881 Sensitive: D – Preclinical REC-4881 Sensitive : D
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D

MEK2 inhibitor

MEK2 inhibitor

Associations(41)

Associations
(41)